Bringing UC Clinical Decision-Making into Focus for 2020: Identify the Right Treatment for the Right Patient at the Right Time
Premiere Date: Wednesday, October 28, 2020This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- ABIM (MOC)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, October 28, 2021
Note: Credit Is No Longer Available
 | David T. Rubin, MD, FACG, AGAF, FACP, FASGE, FRCP (Edinburgh) Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition Director, Inflammatory Bowel Disease Center University of Chicago Medicine Chicago, IL |
 | Adjoa Anyane-Yeboa, MD, MPH Instructor of Medicine Division of Gastroenterology Massachusetts General Hospital Harvard Medical School Boston, MA |
| Millie D. Long, MD, MPH Professor of Medicine Division of Gastroenterology and Hepatology University of North Carolina at Chapel Hill Chapel Hill, NC |
The management of ulcerative colitis (UC) is evolving. In the last 2 years, the American Gastroenterological Association (AGA) and the American College of Gastroenterology (ACG) released updated, evidence-based treatment guidelines with recommendations for disease stratification, prognosis, treatment options, and disease monitoring. Additionally, new efficacy, safety, and comparative effectiveness data from advanced treatment options are now available, and the list is expected to grow with the approval of additional therapies in the future.
In this CME Outfitters live webcast, expert faculty will compare the new AGA and ACG guideline recommendations and discuss recent clinical trial and real-world data in order to provide learners with recommendations on selecting the appropriate therapy for individual patients. In addition, faculty will discuss proven strategies to empower, educate, and engage patients in their UC care.
At the end of this CE activity, participants should be able to:
- Compare new AGA and ACG guideline recommendations on the treatment of UC in order to identify the appropriate course of action for individual patients.
- Differentiate targeted therapies for UC using efficacy, safety, and comparative effectiveness data from clinical trials and real-world experience.
- Empower and educate patients to become an active part of SDM.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Compare new AGA and ACG guideline recommendations on the treatment of UC in order to identify the appropriate course of action for individual patients.
- Differentiate targeted therapies for UC using efficacy, safety, and comparative effectiveness data from clinical trials and real-world experience.
- Describe ways to empower and educate patients to become an active part of SDM.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Gastroenterologists, primary care physicians, PAs, nurse practitioners, nurses, and pharmacists
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs). Universal Activity Number:
Live: 0376-0000-20-127-L01-P
Enduring: 0376-20-127-H01-P
Type: Knowledge-based
ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Learning Format:
Live activity
Enduring material
Royal College MOC Credit:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Note to PAs: PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME or a recognized state medical society.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Rubin reports that he receives grants from AbbVie Inc.; Genentech, Inc./Roche; Janssen Pharmaceuticals, Inc.; Prometheus Laboratories Inc.; Shire; and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for AbbVie Inc.; AbGenomics; Allergan; Biomica; Boehringer Ingelheim; Bristol-Myers Squibb Company; Celgene Corporation/ Syneos Health; Check-Cap; Dizal Pharmaceutical; Eli Lilly and Company; GalenPharma/Atlantica; Genentech, Inc./Roche; Gilead Sciences, Inc.; GlaxoSmithKline; Ichnos Sciences SA; InDex Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Narrow River Management; Pfizer Inc.; Prometheus Laboratories Inc.; Reistone Biopharma; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and Techlab, Inc. He is a stock shareholder (directly purchased) in AbGenomics and Biomica. He receives other financial or material support as Co-Founder and CFO of Cornerstones Health, Inc.; and Co-Founder of GoDuRn, LLC. (non-profit).
Dr. Anyane-Yeboa reports she serves on the advisory committee for Pfizer Inc. She is a consultant for SidekickHealth.
Dr. Long reports that she receives grants and research support from Pfizer Inc. and Takeda Pharmaceuticals U.S.A., Inc. She is a consultant for AbbVie Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Prometheus; Takeda Pharmaceuticals U.S.A., Inc.; TARGET PharmaSolutions, Inc.; and UCB, Inc.
Olga Askinazi, PhD (planning committee) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
MM-106LS-102820-20
